phrykt

Palisade Bio, Inc. (PALI): who owns it and who trades it

As of Nov 16, 2026, PALI insiders reported 4 open-market sales worth $421K and 10 purchases worth $297K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was John David Finley (CEO), with $311K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Palisade Bio

From the latest filings

Overall: more buying than selling. Funds and insiders mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns PALI

124 funds and institutions reported PALI shares worth $363M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Soleus Capital Management, L.P. with 7.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Soleus Capital Management, L.P.7.9%
B Group, Inc.6.9%
Ameriprise Financial Inc6.7%
Jupiter Topco LLC6.4%
BlackRock, Inc.6.3%
Octagon Capital Advisors LP6.2%
Perceptive Advisors LLC5.1%
Ra Capital Management, L.P.4.3%
Franklin Resources Inc3.5%
Point72 Asset Management, L.P.3.2%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Soleus Capital Management, L.P.13.06M7.88%$27.3MNew
B Group, Inc.11.41M6.88%$23.9MNo change
Ameriprise Financial Inc11.08M6.68%$23.2M+27%
Jupiter Topco LLC10.69M6.44%$22.4MNew
BlackRock, Inc.10.44M6.29%$21.8M+456%
Octagon Capital Advisors LP10.28M6.19%$21.5MNo change
Perceptive Advisors LLC8.43M5.08%$17.6M-6%
Ra Capital Management, L.P.7.12M4.29%$14.9MNo change
Franklin Resources Inc5.79M3.49%$12.1MNo change
Point72 Asset Management, L.P.5.25M3.17%$11M+1176%
Boxer Capital Management, LLC4.80M2.89%$10MNo change
Adage Capital Partners Gp, L.l.c.4.50M2.71%$9.4MNo change
Eversept Partners, LP4.18M2.52%$8.7M-16%
Geode Capital Management, LLC3.76M2.27%$7.9M+143%
Wellington Management Group LLP3.70M2.23%$7.7M+28%
Goldman Sachs Group Inc3.58M2.16%$7.5M-33%
Federated Hermes, Inc.3.14M1.89%$6.6MNo change
Squadron Capital Management LLC3.00M1.81%$6.3MNo change
Propel Bio Management, LLC2.58M1.56%$5.4M+132%
Vestal Point Capital, LP2.50M1.51%$5.2MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, PALI insiders reported $297K of open-market purchases and $421K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$297K
10 trades, 2 people
Sales, 12 months
$421K
4 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 2, 2026
Filed Oct 5, 2026

Purchases and sales by month

$410K$410KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 2, 2026Donald Allen WilliamsDirectorPurchase10,000$1.46$14.6KForm 4
Oct 1, 2026Donald Allen WilliamsDirectorPurchase10,000$1.42$14.2KForm 4
Jul 9, 2026Robert Baltera Jr.DirectorPurchase25,000$1.96$49KForm 4
Jul 8, 2026Robert Baltera Jr.DirectorPurchase20,000$1.99$39.8KForm 4
Jul 7, 2026Robert Baltera Jr.DirectorPurchase30,000$2.03$60.9KForm 4
Jul 7, 2026Mitchell Lawrence JonesChief Medical OfficerSale51,880$2.05$106KForm 4
Jul 7, 2026John David FinleyCEOSale146,798$2.07$304KForm 4
Jul 6, 2026Robert Baltera Jr.DirectorPurchase20,000$2.05$41KForm 4
Jul 2, 2026Robert Baltera Jr.DirectorPurchase10,000$1.98$19.8KForm 4
Jul 1, 2026Robert Baltera Jr.DirectorPurchase20,000$1.98$39.6KForm 4
Feb 12, 2026Mitchell Lawrence JonesChief Medical OfficerSale1,989$1.75$3.5KForm 4
Feb 12, 2026John David FinleyCEOSale3,896$1.75$6.8KForm 4
Jan 16, 2026Donald Allen WilliamsDirectorPurchase5,000$1.67$8.3KForm 4
Jan 9, 2026Donald Allen WilliamsDirectorPurchase5,000$1.88$9.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
John David FinleyCEO, CFO, Director–$311KJul 7, 2026
Robert Baltera Jr.Director$250K–Jul 9, 2026
Mitchell Lawrence JonesChief Medical Officer–$110KJul 7, 2026
Donald Allen WilliamsDirector$46.5K–Oct 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PALI short interest

High short interest. 16.8% of PALI shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 9%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 29.29M PALI shares were sold short, 16.8% of the shares outstanding, down 7.7% from the report before. At the average daily volume of 3.78M shares, buying them all back would take about 7.8 trading days (days to cover).

Shares short, % of all shares

16.8%May 15Oct 3023.2%

Days to cover

7.8May 15Oct 3024.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202629.29M16.81%-8%3.78M7.8
Oct 15, 202631.75M18.22%+2%1.98M16.0
Sep 30, 202631.02M17.80%+2%5.12M6.1
Sep 15, 202630.27M17.37%-2%2.20M13.8
Aug 31, 202630.90M17.73%-7%1.62M19.1
Aug 14, 202633.39M19.16%-1%1.52M22.0
Jul 31, 202633.70M20.32%-9%2.31M14.6
Jul 15, 202637.02M22.32%+15%3.71M10.0
Jun 30, 202632.13M19.37%+2%6.01M5.3
Jun 15, 202631.52M19.00%+2%2.65M11.9
May 29, 202630.81M18.57%+14%2.86M10.8
May 15, 202626.92M16.23%+3%2.59M10.4

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Palisade Bio company events

Palisade Bio filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Aug 10, 2026ResultsReleased financial results. Filing
  3. Jun 11, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Jordan Zwick to Board of Directors On June 10, 2026, the Board of Directors of Palisade Bio, Inc. expanded the size of the Board from five… Filing
  4. May 12, 2026ResultsReleased financial results. Filing
  5. Apr 2, 2026AnnouncementIn preparation for the expected Phase 2 study of PALI-2108 for the treatment of patients with moderate to severe Ulcerative Colitis, and in order to expedite the enrollment of patients, on March 30, 2026, Palisade Bio, Inc. entered into a master services agreement with Iterative Scopes, Inc. d/b/a… Filing
  6. Dec 4, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Palisade Bio financials

Famous investors that hold PALI

2 of the 50 well-known investors we track reported holding PALI in their latest 13F filing. The largest position is Steve Cohen's, worth $7.9M.

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20265.87M$7.9M0.0%+12%
Israel Englander · Millennium ManagementQ3 2026917,062$1.2M0.0%-2%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 8 filings named PALI in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Ameriprise Financial, Inc.13G/A8.4%
Nov 16, 2026Ameriprise Financial, Inc.13G/A8.4%
Nov 16, 2026RA Capital Management, L.P.13G/A9.9%
Nov 16, 2026RA Capital Management, L.P.13G/A9.9%
Nov 9, 2026Soleus Capital Master Fund, L.P.13G/A8.6%
Nov 9, 2026Soleus Capital Master Fund, L.P.13G/A8.6%
Oct 30, 2026Vanguard Capital Management13G5.2%
Oct 30, 2026Vanguard Capital Management13G5.2%

Questions about Palisade Bio, Inc. (PALI) stock

Who owns the most PALI stock?

The largest reported owner of Palisade Bio, Inc. (PALI) is Soleus Capital Management, L.P., with 7.9% of the company. In total, 124 funds and institutions reported holding PALI at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are PALI insiders buying or selling?

In the last 12 months, PALI insiders reported 10 open-market purchases worth $297K and 4 sales worth $421K. The latest trade was on Oct 2, 2026. See every trade.

What is the short interest in PALI?

As of Oct 30, 2026, 29.29M PALI shares were sold short, 16.8% of the shares outstanding, down 7.7% from the report before. At the average daily volume of 3.78M shares, buying them all back would take about 7.8 trading days (days to cover). See the history.

Which famous investors hold PALI?

2 of the 50 well-known investors we track reported PALI in their latest 13F filing, including Steve Cohen, Israel Englander. The largest position is worth $7.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.